MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
Ratios
4 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross Margin | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | |
|
EPS Growth
|
- - | -112,031.15 | 67.84 | 66.82 | |
| EPS USD | -0.61 | -684.00 | -220.00 | -73.00 | |
| Return on Assets (ROA) | -0.08 | -554.03 | -83.94 | -6.84 | |
| Return on Equity (ROE) | -0.08 | 460.66 | -131.92 | -7.26 | |
| Return on Invested Capital (ROIC) | -0.09 | -1,597.08 | -132.36 | -10.86 | |
| Solvency | |||||
| Equity Ratio | - - | -100 | - - | - - | |
| Debt/Assets | 0.05 | 154.92 | 0.37 | 0.70 | |
| Debt/Equity | 0.05 | -128.81 | 0.58 | 0.75 | |
| Debt/EBITDA | 1,208.27 | -12.99 | 60.29 | 826.97 | |
|
Debt/Capitalization
|
0.05 | 447.09 | 0.57 | 0.74 | |
| Long-Term Debt/Capitalization | - - | - - | 0.26 | 0.50 | |
| Interest Debt per Share USD | - - | 1.91 | -0.01 | 0.08 | |
| Debt Growth | - - | 25,734.01 | -98.12 | 1,208.61 | |
| Liquidity | |||||
| Current Ratio | 1,293.30 | 45.70 | 998.13 | 5,159.38 | |
| Quick Ratio | 1,067.19 | 38.83 | 943.61 | 5,138.29 | |
| Cash Ratio | 1,067.19 | 38.12 | 515.37 | 4,527.23 | |
| Operating Cash Flow Ratio | -200 | -100 | -700 | -400 | |
| Turnover | |||||
| Inventory Turnover | - - | 0.38 | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | |
| Payables Turnover | - - | 0.35 | 4.85 | 2.38 | |
|
Asset Turnover
|
- - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | |
| Coverage | |||||
| Interest Coverage | - - | - - | 10,995.08 | - - | |
| Asset Coverage | 200,700 | - - | 24,500 | 14,000 | |
| Cash Flow Coverage (CFGR) | -545.43 | -234.50 | -19,779.85 | -1,156.83 | |
| EBITDA Coverage | - - | - - | 10,900 | - - | |
| Dividend Coverage | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | |
| Market Prospects | |||||
| Dividend Yield | - - | - - | - - | - - | |
| Earnings Yield | -0.05 | -69.18 | -20.92 | -1.21 | |
|
Price/Earnings (P/E)
|
-185,311.05 | -144.56 | -477.93 | -8,238.64 | |
| Price/Earnings Growth (PEG) | - - | - - | 7.05 | 123.30 | |
|
Price/Book (P/B)
|
149.65 | -665.90 | 630.48 | 598.48 | |
| Price/Tangible Book (P/TB) | 149.65 | -665.90 | 630.48 | 598.48 | |
| Price/Sales (P/S) | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-53,153.49 | -220.45 | -551.57 | -6,934.64 | |
| Price/Free CF (P/FCF) | -53,153.49 | -220.14 | -551.41 | -6,888.80 | |
| Price/Operating CF (P/OCF) | -53,153.49 | -220.45 | -551.57 | -6,934.64 |